Prévisions du marché européen des conjugués d\'anticorps et de médicaments jusqu\'en 2030 – Analyse régionale – Par technologie (lien clivable et lien non clivable), application (cancer du sang, cancer du sein, cancer de l\'ovaire, cancer urothélial et autres) et canal de distribution (pharmacies hospitalières, vente au détail Pharmacies et pharmacies en ligne)
Le marché européen des conjugués anticorps-médicaments était évalué à 2 263,14 millions de dollars US en 2022 et devrait atteindre 7 947,86 millions de dollars US d’ici 2030 ; on estime que sa croissance est de 17,0 % entre 2022 et 2030.
L\'augmentation des investissements pour développer les ADC alimente le marché européen des conjugués anticorps-médicaments
Les ADC changent la donne dans le domaine de l\'oncologie ; ceux-ci sont largement acceptés pour traiter le cancer du sein. Plusieurs entreprises investissent énormément pour développer de nouveaux ADC. En mai 2022, Evotec SE a annoncé un énorme investissement stratégique en actions dans Tubulis GmbH pour développer des ADC. Evotec SE a investi 64 millions de dollars américains (60 millions) lors du cycle de financement Tubliss série B, dirigé par Andera Partners. De même, en juin 2022, Spirea Limited a annoncé avoir reçu des investissements de 3 millions de dollars américains (
Europe Antibody Drug Conjugates Strategic Insights
Strategic insights for Europe Antibody Drug Conjugates involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
The regional scope of Europe Antibody Drug Conjugates refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
Get more information on this report
Identical Market Reports with other Region/Countries
How big is the Europe Antibody Drug Conjugates Market?
The Europe Antibody Drug Conjugates Market is valued at US$ 2,263.14 Million in 2022, it is projected to reach US$ 7,947.86 Million by 2030.
What is the CAGR for Europe Antibody Drug Conjugates Market by (2022 - 2030)?
As per our report Europe Antibody Drug Conjugates Market, the market size is valued at US$ 2,263.14 Million in 2022, projecting it to reach US$ 7,947.86 Million by 2030. This translates to a CAGR of approximately 17.0% during the forecast period.
What segments are covered in this report?
The Europe Antibody Drug Conjugates Market report typically cover these key segments-
Technologie (liant clivable, liant non clivable)
Demande (cancer du sang, cancer du sein, cancer de l\'ovaire, cancer urothélial)
Canal de distribution (pharmacies hospitalières, pharmacies de détail, pharmacies en ligne)
What is the historic period, base year, and forecast period taken for Europe Antibody Drug Conjugates Market?
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Antibody Drug Conjugates Market report:
Historic Period : 2020-2021
Base Year : 2022
Forecast Period : 2023-2030
Who are the major players in Europe Antibody Drug Conjugates Market?
The Europe Antibody Drug Conjugates Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
ADC Therapeutics SA
Pfizer Inc
Hoffmann-La Roche Ltd
ImmunoGen, Inc
GSK Plc
Gilead Sciences Inc
AstraZeneca Plc
Astellas Pharma Inc
Takeda Pharmaceutical Co Ltd
Who should buy this report?
The Europe Antibody Drug Conjugates Market report is valuable for diverse stakeholders, including:
Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.
Essentially, anyone involved in or considering involvement in the Europe Antibody Drug Conjugates Market value chain can benefit from the information contained in a comprehensive market report.
Get Free Sample For Europe Antibody Drug Conjugates Market
1. Complete the form
2. Check your inbox (and spam/junk folder)
3. Your Personal Data is Secure with us
GDPR + CCPA Compliant
Personal & transactional information is kept safe from unauthorized use.
WHAT'S INCLUDED IN FULL REPORT : Market Dynamics,
Competitive Analysis and Assessment, Define Business Strategies, Market Outlook and
Trends, Market Size and Share Analysis, Growth Driving Factors, Future Commercial
Potential, Identify Regional Growth Engines